reports
SELLAS Life Sciences Presents Positive Phase 2 Data of SLS009 in Combi...
SELLAS Life Sciences Presents Positive Phase 2 Data of SLS009 in Combination with AZA/VEN in Relapsed/Refractory AML-MR at ASH 2025 SLS009 in combination with AZA/VEN achieved a 46% overall response rate across all cohorts, a 58% overall response rate in patients with one prior line of therapy, and encouraging survival outcomes in heavily-pretreated AML-MR following prior VEN-based treatmentMedian overall survival (mOS) of 8.9 months in the least pretreated patient cohort; across all cohorts, mOS was not yet reached in patients with one prior line of therapy vs historical benchmark of appro...
Sellas Life Sciences Group Inc: 1 director
A director at Sellas Life Sciences Group Inc bought 63,400 shares at 1.590USD and the significance rating of the trade was 73/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last t...
SELLAS Life Sciences Reports Third Quarter 2025 Financial Results and ...
SELLAS Life Sciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update – Hosted Virtual R&D Day Highlighting GPS and SLS009 Programs in AML – – Positive Phase 2 Data for SLS009 in R/R AML Accepted for Presentation at ASH 2025; Initiation of Trial Including Newly Diagnosed First-Line AML Patients Expected in Q1 2026 – – $44.3 Million in Cash and Cash Equivalents as of September 30, 2025; Additional $29.1 Million in Proceeds Received in October 2025 through Warrant Exercises – NEW YORK, Nov. 12, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: S...
SELLAS Life Sciences Announces Presentation of Phase 2 Data of SLS009 ...
SELLAS Life Sciences Announces Presentation of Phase 2 Data of SLS009 in Combination with Azacitidine and Venetoclax in Relapsed/Refractory AML with MDS-Related Changes (AML-MR) at the 2025 American Society of Hematology (ASH) Annual Meeting NEW YORK, Nov. 03, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that data from its ongoing Phase 2 study of SLS009 for the treatment of relapsed ...
SELLAS Life Sciences Group Announces Exercise of Existing Warrants Hel...
SELLAS Life Sciences Group Announces Exercise of Existing Warrants Held by a Current Institutional Investor for $31 Million in Gross Proceeds NEW YORK, Oct. 27, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced the immediate exercise of warrants, previously issued in March and August 2024 (the “Existing Warrants”), to purchase up to 22,363,714 shares of its common stock for gross cash proce...
SELLAS Life Sciences to Participate in the J.P. Morgan U.S. Opportunit...
SELLAS Life Sciences to Participate in the J.P. Morgan U.S. Opportunities Forum Company to conduct 1x1 meetings with investors on Wednesday, November 12th NEW YORK, Oct. 22, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that Dr. Angelos Stergiou, President and Chief Executive Officer of SELLAS, will participate in the J.P. Morgan U.S. Opportunities Forum, which is being held on Wed...
SELLAS Life Sciences to Present In Vivo Preclinical Data Demonstrating...
SELLAS Life Sciences to Present In Vivo Preclinical Data Demonstrating Statistically Significant Survival Benefit of SLS009 in T-Cell Prolymphocytic Leukemia at the European Society for Medical Oncology (ESMO) Congress 2025 Preclinical data support SLS009 as a monotherapy or in combination with venetoclax for the treatment of T-PLL, a rare and highly aggressive form of mature T-cell leukemia NEW YORK, Oct. 13, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development o...
SELLAS Life Sciences Group to Host Virtual R&D Day on October 29, 2025...
SELLAS Life Sciences Group to Host Virtual R&D Day on October 29, 2025: Advancing Novel Therapies in Acute Myeloid Leukemia (AML): An Overview of the Ongoing Phase 3 REGAL Trial of Galinpepimut-S (GPS) and SLS009 Program Update NEW YORK, Sept. 30, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that it will host a virtual R&D Day on Wednesday, October 29, 2025 at 10:00 AM ET featuring key...
SELLAS Life Sciences Group Announces Exercise of Existing Warrants Hel...
SELLAS Life Sciences Group Announces Exercise of Existing Warrants Held by a Current Institutional Investor for $23.6 Million in Gross Proceeds NEW YORK, Sept. 11, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced the immediate exercise of warrants, previously issued in January 2025, to purchase up to 19,685,040 shares of its common stock for gross cash proceeds of approximately $23.6 milli...
SELLAS Life Sciences Reports Second Quarter 2025 Financial Results and...
SELLAS Life Sciences Reports Second Quarter 2025 Financial Results and Provides Corporate Update - Positive IDMC Recommendation to Continue Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in AML Without Modification; Final Analysis Anticipated by Year-end 2025 –- Reported Positive Phase 2 Results of SLS009 in Relapsed/Refractory (r/r) Acute Myeloid Leukemia (AML) with Trial Meeting All Primary Endpoints; Full Data Presentation Expected Later This Year -- Alignment with FDA to Advance SLS009 in a First-Line AML Trial with Enrollment Anticipated by Q1 2026 -- $25.3 million in Cash and Cas...
SELLAS Life Sciences Announces Independent Data Monitoring Committee P...
SELLAS Life Sciences Announces Independent Data Monitoring Committee Periodic Review and Positive Recommendation to Continue Pivotal Phase 3 REGAL Trial of GPS in AML Without Modification - Final Analysis Anticipated by Year-End Upon Occurrence of 80 Events - NEW YORK, Aug. 07, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that the Independent Data Monitoring Committ...
SELLAS Meets All Primary Endpoints in Phase 2 Trial of SLS009 in r/r A...
SELLAS Meets All Primary Endpoints in Phase 2 Trial of SLS009 in r/r AML and Receives FDA Guidance to Advance into First-Line Therapy Study The Trial Exceeded Target Overall Response Rate (ORR) of 20%, with 44% Response Rate Among Patients with Acute Myeloid Leukemia-Myelodysplasia-Related Changes (AML MR) Treated at Optimal Dose of 30 mg Twice a Week (BIW) and 50% in AML MR with Myelomonocytic/Myelomonoblastic (M4/M5) SubtypeMedian Overall Survival (mOS) of 8.9 Months in Patients with AML MR and 8.8 mOS in Relapsed or Refractory to Venetoclax-Based Regimens at 30 mg BIW Dose Level Surpasse...
SELLAS Life Sciences Appoints Linghua Wang, MD, PhD, to Scientific Adv...
SELLAS Life Sciences Appoints Linghua Wang, MD, PhD, to Scientific Advisory Board NEW YORK, July 07, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced the addition of Linghua Wang, MD, PhD, to its Scientific Advisory Board (SAB). Dr. Wang is a widely respected leader in cancer research and translational science, and she joins the Company’s SAB shortly after the appointments of Philip C. Am...
SELLAS Life Sciences to be Added to Russell 3000® and Russell 2000® In...
SELLAS Life Sciences to be Added to Russell 3000® and Russell 2000® Indexes NEW YORK, June 24, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that the Company will be added to the Russell 3000® and Russell 2000® Indexes, effective after the U.S. market close on June 27, as part of the 2025 Russell indexes annual reconstitution. The Russell 3000® Index tracks the performance of the large...
SELLAS Life Sciences Expands Scientific Advisory Board with Addition o...
SELLAS Life Sciences Expands Scientific Advisory Board with Addition of Two World-Renowned Hematology and Oncology Experts New appointments of Drs. Philip C. Amrein and Alex Kentsis Validate Lead Galinpepimut-S and SLS009 Programs as Company Approaches Key Inflection Points This Year NEW YORK, June 05, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced the appointment of two distinguished...
SELLAS Presents Preclinical Efficacy of SLS009 in ASXL1 Mutated Colore...
SELLAS Presents Preclinical Efficacy of SLS009 in ASXL1 Mutated Colorectal Cancer at 2025 ASCO Annual Meeting - ASCO Presentation Supports SLS009 as a Potential Targeted Therapy for ASXL1 Mutated Colorectal Cancer – - 22,500 New Cases of Colorectal Cancer with High Microsatellite Instability per Year in the US: 55% ASXL1m Frequency – NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer ind...
SELLAS Life Sciences to Participate in Fireside Chat at the A.G.P. Vir...
SELLAS Life Sciences to Participate in Fireside Chat at the A.G.P. Virtual Healthcare Company Showcase NEW YORK, May 20, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that Dr. Angelos Stergiou, President and Chief Executive Officer of SELLAS, will participate in a fireside chat at the A.G.P. Virtual Healthcare Company Showcase on Wednesday, May 21, 2025 at 8:20 am ET. A.G.P. Virtual H...
SELLAS Life Sciences Announces First Pediatric AML Patient Dosed in th...
SELLAS Life Sciences Announces First Pediatric AML Patient Dosed in the Ongoing Phase 2 Trial of SLS009 r/r AML - First ASXL1 Pediatric Acute Myeloid Leukemia (AML) Patient Dosed at MD Anderson Cancer Center: Program Supported by Rare Pediatric Disease Designation (RPDD) NEW YORK, May 15, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that the first pediatric AML patient has been dose...
SELLAS Life Sciences Reports First Quarter 2025 Financial Results and ...
SELLAS Life Sciences Reports First Quarter 2025 Financial Results and Provides Corporate Update – Announced Positive Overall Survival in Cohort 3 from the Ongoing Phase 2 Trial of SLS009 (tambiciclib) in Relapsed/Refractory (r/r) Acute Myeloid Leukemia (AML) Demonstrating 8.9 mOS in AML-MRC and 8.8 mOS in All r/r to Venetoclax-Based Regimens Patients – – SLS009 Shows Promising Efficacy in Pediatric Acute Lymphoblastic Leukemia (ALL) Xenograft Models – – Final Analysis of Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in AML Anticipated in 2025 – – $28.4 million in Cash and Cash Equi...
SELLAS Unveils Breakthrough Preclinical Data Highlighting Efficacy of ...
SELLAS Unveils Breakthrough Preclinical Data Highlighting Efficacy of SLS009 in TP53 Mutated AML at the 2025 AACR Conference New Data Suggest SLS009 (tambiciclib) May Overcome Resistance to Azacitidine-Venetoclax Regimen and Trigger Apoptosis of TP53 Mutated AML Cells NEW YORK, April 28, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that preclinical efficacy of SLS009 in TP53 mutated ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.